Beata Ostrowska

Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie | COI · department of Lymphproliferative Disease

Introduction: Anti-CD20 antibody plus chemotherapy is one of the standard treatments for follicular lymphoma (FL) patients in need of therapy. Obinutuzumab-based regimens demonstrated improved progression- free survival (PFS) compared to rituximab plus chemotherapy (NCT01332968). Recently, the course of treatment of FL patients was disrupted by the...

Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real‐world patients are not included. Recently,the diagnosis and treatment of PCNSL patients was confounded by the COVID‐19 pandemic. In particular, treatment with high‐dose cytarabine was linked to increased...

Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85–95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggres...

The efficacy of salvage treatment of diffuse large B‐cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O‐IVAC) was evaluated in a single‐arm study. Dosing was modified for elderly patients. Patients received up to six cycl...

Introduction: Obinutuzumab-based induction immunochemotherapy was demonstrated to improve the outcome of patients with follicular lymphoma (FL) comparing to the regimens with rituximab in GALLIUM study (NCT01332968). The infusion related reactions (IRRs) occur in more than half of FL patients during the first obinutuzumab administration. Therefore,...

(1) Background: T-cell lymphoblastic lymphoma (T-LBL) is extremely rare and highly aggressive, with no practical risk model defined yet. The prognostic value of T-LBL immunological subtypes is still a matter of controversy. (2) Methods: We re-evaluated 49 subsequent adult T-LBL patients treated according to the German Multicenter Study Group for Ad...

Castleman disease is a very rare, lymphoproliferative disease, driven by dysregulation of the cytokine interleukin 6 (IL-6) and other proinflammatory cytokines with the development of symptoms of systemic inflammation, reactive proliferation of lymphocytes, and damage to numerous organs. HHV-8 infection plays a major role in the pathogenesis of hum...

e20034 Background: Plasmablastic lymphoma (PBL) is a rare CD20-negative lymphoma with an aggressive clinical course and short median survival ranging from 9 to 32 months. It is often associated with HIV infection but it also affects immunocompetent patients. Due to the rare occurrence most data comes from small, retrospective series. Methods: This...

Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive, extranodal form of non-Hodgkin lymphoma, predominantly diagnosed as primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL). Fast and precise diagnosis of PCNSL is critical yet challenging. microRNAs, important regulators in physiology and patholog...

J Clin Oncol 35, 2017 (suppl; abstr 7560) Poster Board Number: Poster Session (Board #322)

7560 Background: 2016 update of the WHO 2008 classification of lymphoid neoplasms introduced new categories of highly aggressive B lymphomas (BCL): high grade B lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (HGBLR) and HGBL not otherwise specified (NOS). The prognosis for HGBL is generally considered poor, the optimal therapy is unkn...

Background: MYC, BCL2 and BCL6 are known to be altered in high grade B-cell lymphoma (HGBL). Double/triple-hit lymphomas (D/THLs) are characterized by chromosomal rearrangements of MYC, BCL2 and/or BCL6. D/THLs have been included in the updated 2016 WHO classification, as a new category of “High grade B-cell lymphoma with rearrangements” (HGBL-R) o...

Background: MYC, BCL2 and BCL6 are known to be altered in high grade B-cell lymphoma (HGBL). Double/triple-hit lymphomas (D/THLs) are characterized by chromosomal rearrangementsof MYC, BCL2 and/or BCL6. D/THLs have been included in the updated 2016 WHO classification, as a new category of "High grade B-cell lymphoma with rearrangements" (HGBL-R) or...

Background: Secondary central nervous system (CNS) involvement is an unfavorable risk factor with an impact on overall survival (OS) in malignant lymphoma. Methods: We conducted a retrospective analysis of secondary CNS involvement in patients diagnosed with Diffuse Large B-Cell lymphoma (DLBCL) on the first line treatment and after the end of trea...

Background: Secondary central nervous system (CNS) involvement is an unfavorable risk factor with an impact on overall survival (OS) in malignant lymphoma. Methods: We conducted a retrospective analysis of secondary CNS involvement in patients diagnosed with Diffuse Large B-Cell lymphoma (DLBCL) on the first line treatment and after the end of trea...

Background: Median age of patients (pts) with diffuse large B cell lymphoma (DLBCL) is 65 years and the prevalence of DLBCL in pts aged over 75 years is rapidly growing. In younger patients, standard induction RCHOP immunotherapy results in about 70% of cure. On the other hand, older pts are frequently considered unfit for standard RCHOP treatment,...

Abstract Aim: Testicular lymphoma is characterised by aggressive clinical course and in cases of treatment failure frequently involviesCNS and contralateral testis. Late relapses have been reported in occasional series. Here we looked at clinical features and outcome of patients treated at a single instiution over a period of 25 years. Methods: We...

Background Currently recommended treatment for the primary CNS lymphoma (PCNSL) involves high-dose methotrexate (HM) preferably in combination with high-dose cytarabine (HA). However, nearly half of the patients present with locally advanced disease and poor performance status (PS) prohibiting the use of this biologically challenging therapy. On th...

Early non-haematological toxicity of high dose therapy (HDT) and autologous haematopoietic cell transplantation (autoHCT) can be more hazardous in older patients (pts) with comorbidities. The aim of the study was to analyze incidence and grade of the organ-related early complications up to 30 days post-transplant period in elderly lymphoma patients...

e18512 Background: Anaplastic large cell lymphoma ALK positive (ALCL ALK+) is frequently referred to as easily curable disease, however, patients with more than 1 IPI risk factors have a poor outcome. ALCL ALK negative (ALCL ALK-) have usually higher IPI score and there is no general consensus on what treatment is the optimal. We evaluated data on...

Background: Anaplastic large cell lymphoma ALK positive (ALCL ALK+) is frequently referred to as easily curable disease, however, patients with more than 1 IPI risk factors have a poor outcome. ALCL ALK negative (ALCL ALK-) have usually higher IPI score and there is no general consensus on what treatment is the optimal. We evaluated data on 26 cons...

Application of the anti-CD20 monoclonal antibody rituximab into front-line regimens to treat diffuse large B cell lymphoma (DLBCL) resulted in improved survival. Despite this progress, many patients develop refractory or recurrent DLBCL and then undergo autologous hematopoietic stem cell transplantation (autoHCT). It is unclear whether pre-transpla...

Lymphoid malignancies may be accompanied by primary or secondary involvement of central nervous system (CNS). The risk is particularly high in course acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), Burkitt lymphoma (BL), selected patients with diffuse large B cell lymphoma (DLBCL) and unclassifiable large B cell lymphoma with featu...

Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed non-Hodgkin's lymphoma. Results of large retrospective studies indicate the risk of relapse within the central nervous system (CNS) at a level of approximately 5%, with elevated serum LDH and the presence of at least two extranodal sites being the major risk factors. Relapses in t...

3928 Poster Board III-864 Background and aim In contrast to T lymphoblastic leukemia (T-ALL), there is a little data on the incidence and prognostic value of immunologic subtypes of adult T lymphoblastic lymphoma (T-LBL) as the use of flow cytometry in the absence of leukemia may be problematic. Our aim was to define immunophenotype of T-LBL and T...

Bcl-2 and Bcl-6 protein expression has been reported to predict progression-free (PFS) and overall (OS) survival of patients with Diffuse Large B-cell Lymphoma (DLBCL) in retrospective and prospective clinical studies. Reports on Bcl-2 expression frequency and predictive value have been conflicting. In the current study, paraffin-embedded tissue sp...